252 related articles for article (PubMed ID: 33744052)
1. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
Nwogu IB; Jones M; Langley T
Vaccine; 2021 Apr; 39(16):2201-2213. PubMed ID: 33744052
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
Beck E; Klint J; Neine M; Garcia S; Meszaros K
Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
[TBL] [Abstract][Full Text] [Related]
4. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
5. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
[No Abstract] [Full Text] [Related]
6. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
[TBL] [Abstract][Full Text] [Related]
8. Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.
Presa J; Burman C; Tort MJ; Cane A; Bocchini JA
Hum Vaccin Immunother; 2023 Dec; 19(1):2212570. PubMed ID: 37257838
[TBL] [Abstract][Full Text] [Related]
9. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
[TBL] [Abstract][Full Text] [Related]
10. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
Watson PS; Turner DP
Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
14. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
Findlow J; Nuttens C; Kriz P
Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
[TBL] [Abstract][Full Text] [Related]
15. Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data.
Zografaki I; Detsis M; Del Amo M; Iantomasi R; Maia A; Montuori EA; Mendez C
Expert Rev Vaccines; 2023; 22(1):545-562. PubMed ID: 37316234
[TBL] [Abstract][Full Text] [Related]
16. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.
Hogea C; Van Effelterre T; Vyse A
Hum Vaccin Immunother; 2016; 12(2):451-66. PubMed ID: 26308796
[TBL] [Abstract][Full Text] [Related]
17. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
Tzanakaki G; Xirogianni A; Tsitsika A; Clark SA; Kesanopoulos K; Bratcher HB; Papandreou A; Rodrigues CMC; Maiden MCJ; Borrow R; Tsolia M
Vaccine; 2021 Mar; 39(11):1621-1630. PubMed ID: 33597116
[TBL] [Abstract][Full Text] [Related]
18. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
Christensen H; Hickman M; Edmunds WJ; Trotter CL
Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
[TBL] [Abstract][Full Text] [Related]
19. Serogroup B meningococcal vaccination practice patterns on college campuses.
Haimowitz R; Torres R; Caleb S; Thompson D; Smith A; Ciotoli C; Dannenbaum M; Fu LY
Vaccine; 2020 Oct; 38(46):7350-7356. PubMed ID: 33010977
[TBL] [Abstract][Full Text] [Related]
20. Analysis of meningococcal vaccine uptake in patients with invasive meningococcal disease, Czech Republic, 2006-2022.
Křížová P; Okonji Z; Honskus M
Epidemiol Mikrobiol Imunol; 2023; 72(4):243-247. PubMed ID: 38242709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
